发明名称 RING-FUSED COMPOUND
摘要 The present invention relates to a compound that has URAT1 inhibitory action, and a URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition comprising the compound. More specifically, the present invention relates to a compound represented by Formula (I) below. [in the formula, R 1 is -Q 1 -A 1 and the like; ---- is a double bond or a single bond; when ---- is a double bond, W 1 is a nitrogen atom or a group represented by the general formula: =C(R a )-, and W 2 is a nitrogen atom or a group represented by the general formula: =C(R b ) -; when ---- is a single bond, W 1 is a group represented by the general formula: -C(R aa )(R ab )- or a group represented by the general formula: -(C=O) -, and W 2 is a group represented by the general formula: C(R ba )(R bb )-, a group represented by the general formula: - (C=O) - or a group represented by the general formula: -N(R bc )-; W 3 , W 4 and W 5 are each independently a nitrogen atom or a methine group and the like that may have a substituent; X is a single bond, an oxygen atom and the like; Y is a single bond or (CR Yi R Yi' ) n ; and Z is a hydroxyl group or COOR 2 and the like.
申请公布号 EP2669270(A4) 申请公布日期 2014.07.02
申请号 EP20120739424 申请日期 2012.01.30
申请人 SATO PHARMACEUTICAL CO., LTD. 发明人 NAGAI KEITA;NAGASAWA KOH;TAKAHASHI HIROBUMI;BABA MOTOAKI;FUJIOKA SHINICHI;KONDOH ERI;TANAKA KENICHI;ITOH YOSHIKI
分类号 C07D209/08;A61K31/404;A61K31/416;A61K31/4184;A61K31/4439;A61P9/10;A61P13/04;A61P13/12;A61P19/02;A61P19/06;A61P43/00;C07D209/30;C07D231/56;C07D235/06;C07D235/08;C07D235/10;C07D401/06;C07D403/04;C07D405/06;C07D409/06;C07D413/06 主分类号 C07D209/08
代理机构 代理人
主权项
地址